

ly used antifibrotic agent, in inducing remission in patients with idiopathic retroperitoneal fibrosis.<sup>1</sup> In addition, biologic therapies such as the B-cell–depleting antibody rituximab and the interleukin-6–receptor blocker tocilizumab induced regression of idiopathic retroperitoneal fibrosis in patients with glucocorticoid-refractory disease.<sup>2,3</sup> Glucocorticoids and rituximab are also effective for patients with IgG4-related disease, a systemic fibroinflammatory condition that may encompass retroperitoneal fibrosis.<sup>4</sup> We believe that these findings are extremely relevant for the management of retroperitoneal fibrosis and that they provide substantial evidence that targeting inflammation may lead to regression of abnormal fibrosing responses.

Maria L. Urban, M.D.  
Lucio Manenti, M.D.  
Augusto Vaglio, M.D., Ph.D.

University Hospital Parma  
Parma, Italy  
augusto.vaglio@virgilio.it

No potential conflict of interest relevant to this letter was reported.

1. Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. *Lancet* 2011;378:338-46.
2. Maritati F, Corradi D, Versari A, et al. Rituximab therapy for chronic periaortitis. *Ann Rheum Dis* 2012;71:1262-4.
3. Vaglio A, Catanoso MG, Spaggiari L, et al. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. *Arthritis Rheum* 2013;65:2469-75.
4. Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. *Ann Rheum Dis* 2015;74:1171-7.

DOI: 10.1056/NEJMc1504848

**THE AUTHORS REPLY:** We agree with Ben Salem and colleagues that several drugs can trigger fibro-

sis in the lungs and heart, as well as in multiple other organs. It should also be pointed out that a number of drugs have been implicated in liver fibrosis, including those that cause chronic drug-induced liver injury,<sup>1</sup> such as amiodarone and methotrexate. Since mechanisms of drug-induced fibrosis remain largely ill defined, and owing to editorial decisions made on the basis of space limitations, we did not pursue this biology in detail. We appreciate its being highlighted here.

Urban and colleagues point to an open-label clinical trial comparing prednisone and tamoxifen in the prevention of relapse in patients with idiopathic retroperitoneal fibrosis.<sup>2</sup> In that study, the authors conclude that prednisone is more effective than tamoxifen. In our review, we noted that treatment of retroperitoneal fibrosis is not available; this statement was based on a lack of evidence from large, randomized, controlled clinical trials (most likely because of the rarity of the disease). Nevertheless, we appreciate the observations regarding potential therapies.

Don C. Rockey, M.D.  
P. Darwin Bell, Ph.D.

Medical University of South Carolina  
Charleston, SC  
roockey@muscc.edu

Joseph A. Hill, M.D., Ph.D.

University of Texas Southwestern Medical Center  
Dallas, TX

Since publication of their article, the authors report no further potential conflict of interest.

1. Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. *Gastroenterology* 2014;147:96-108.
2. Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. *Lancet* 2011;378:338-46.


DOI: 10.1056/NEJMc1504848

## Real-Time Localization of Parathyroid Adenoma during Parathyroidectomy

**TO THE EDITOR:** Parathyroidectomy can be difficult, with poor outcomes if abnormal parathyroid tissue is not fully resected or if critical neck structures, such as the recurrent laryngeal nerves, are injured during surgery. Complications may be more common in patients undergoing second surgeries, since scarring in the central neck can obscure anatomical landmarks, and in those

with aberrant anatomy. We now report the use of intraoperative magnetic resonance imaging (MRI) integrated with real-time navigation to guide parathyroidectomy.

Five patients with primary hyperparathyroidism underwent intraoperative MRI to localize the parathyroid adenoma and recurrent laryngeal nerve for subsequent parathyroidectomy in an



**Figure 1 (previous page). Intraoperative MRI Integrated with Real-Time Navigation to Guide Parathyroidectomy.**

Technetium-99m–labeled sestamibi imaging shows an abnormal tracer uptake, indicating a suspected lesion (Panel A, arrow), as confirmed on ultrasonography (Panel B, arrow). A three-dimensional model generated from preoperative computed tomography shows the anterior view (Panel C), with the parathyroid adenoma clearly visible on intraoperative MRI (Panel D, arrow). The navigation system shows the global view of the surgical instrument (red cylinder) with respect to the neck anatomy, with skin indicated in orange, trachea in aqua, thyroid in yellow, and tumor in green (deformed by tissue manipulation during surgery) and blue (undeformed) (Panel E). The Wingman's view shows the instrument tip and the surrounding anatomy (Panel F), and virtual endoscopy shows the view from the instrument tip (Panel G).

advanced multimodality image-guided operating (AMIGO) suite (Fig. 1).<sup>1</sup> Fiducial markers were placed on the patient, around the surgical site. The MRI consisted of T<sub>1</sub>-weighted VIBE (volumetric interpolated breath-hold examination) sequences, T<sub>2</sub>-weighted BLADE (proprietary name for periodically rotated overlapping parallel lines with enhanced reconstruction [PROPELLER]) sequences, and T<sub>2</sub>-weighted TSE (turbo spin echo) sequences. Using semiautomatic segmentation techniques, we created three-dimensional patient-specific models of the skin, trachea, carotid artery, thyroid, and parathyroid adenoma in the open-source software 3D Slicer.<sup>2,3</sup> We used a modified Bovie pencil that was fitted with an electromagnetic position sensor as a localization probe to assess the position of each structure in three-dimensional space. We developed a navigation software module in 3D Slicer, called EndoscopyNavigation, to track the instrument in real time and to display the instrument with virtual three-dimensional models.

Using the imaging fiducial markers, we mapped the electromagnetic-tracker space to the image space (see the video, available with the full text of this letter at NEJM.org). The displays were arranged so that the surgeon could visualize the instrument and the surrounding anatomy simultaneously. Thereafter, the thyroid edge, trachea, and parathyroid adenoma were localized with the use of the probe, and their position was mapped to the image space. We calculated the target-registration error for the navigation system,

which was defined as the difference in three-dimensional space between the position of seven distinct points on the patient mapped to the image space and their corresponding position on the intraoperative MRI. We computed the minimum distance between the localization probe and the various structures to evaluate the accuracy of the localization.

For the five patients, the mean ( $\pm$ SD) target-registration error was 3.1 $\pm$ 0.3 mm. The minimum distance from the probe was 1.26 mm to the thyroid edge, 0.64 mm to the trachea, and 0.31 mm to the parathyroid adenoma. All parathyroid adenomas were successfully resected, and there were no recurrent laryngeal-nerve palsies or postoperative neck hematomas. In all five patients, postoperative normalization of calcium levels was confirmed.

Thus, the use of intraoperative MRI in conjunction with a navigation system might be a useful tool in the intraoperative identification of parathyroid adenomas. Such a procedure is particularly useful if the glands are ectopic or if a patient has undergone previous surgeries.

Jagadeesan Jayender, Ph.D.

Thomas C. Lee, M.D.

Daniel T. Ruan, M.D.

Brigham and Women's Hospital  
Boston, MA  
druan@partners.org

Supported by grants from the National Center for Research Resources and the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health (P41EB015898 and P41RR019703).

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

1. Advanced multimodality image-guided operating suite (AMIGO). 2012 ([https://www.youtube.com/watch?v=LcZBc\\_po9yQ](https://www.youtube.com/watch?v=LcZBc_po9yQ)).
2. Fedorov A, Beichel R, Kalpathy-Cramer J, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. *Magn Reson Imaging* 2012;30:1323-41.
3. D'Agostino J, Diana M, Vix M, Soler L, Marescaux J. Three-dimensional virtual neck exploration before parathyroidectomy. *N Engl J Med* 2012;367:1072-3.

DOI: 10.1056/NEJMc1415448

Correspondence Copyright © 2015 Massachusetts Medical Society.

**THE JOURNAL'S WEB AND E-MAIL ADDRESSES**

To submit a letter to the Editor: authors.NEJM.org  
For information about the status of a submitted manuscript:  
authors.NEJM.org  
To submit a meeting notice: meetingnotices@NEJM.org  
The Journal's web pages: NEJM.org



A video is available at NEJM.org